People walk past electric truck maker Rivian’s newly opened storefront in Manhattan’s Meatpacking District on June 23, 2023 in New York City.

Spencer Pratt | Getty Images

Check out the companies making headlines in midday trading.

Electric Vehicles — Manufacturers of electric vehicles such as rivian car Shares soared after Tesla’s second-quarter production and delivery figures beat expectations. Rivian rose 17.4 percent, Fisk up 1.4% lucid group Advanced 7%.

XPeng ——The stock price of Xiaopeng Motors listed in the United States rose by 4%. The Chinese electric carmaker’s vehicle deliveries returned to growth. 23,205 vehicles were delivered in the second quarter, an increase of 27% from the previous quarter.

tesla — Shares of the electric car company led by Elon Musk rose 6.9% after deliveries and production beat analysts’ expectations. The second quarter of 2023 marks the fifth consecutive quarter that Tesla has reported higher vehicle production than deliveries.

Chinese Internet Stocks – Chinese technology stocks rose on Monday.this Jinrui CSI China Internet ETF up 2.3 percent, boosted by stocks alibabaup about 0.9%, and Pinduoduo, leading by 3.1%.shares Jingdong An increase of about 3%.

Solar Stocks — Solar Stocks Solar Edge Technologies and Grace Energy They rose 0.5 percent and 1.2 percent, respectively, on Monday.

Semiconductors – Semiconductor stocks rose on Monday.shares Melville Technology and Micron Technology That’s 2.6% and about 1.3% higher, respectively.

apple — Apple shares fell 0.5 percent, according to a person with direct knowledge of the matter, the Financial Times reported. iPhone maker reportedly forced to cut production forecast Its Vision Pro headset. Apple shares closed Friday above a market cap of $3 trillion.

AstraZeneca — Shares of the Cambridge, U.K.-based drugmaker fell 8 percent Announce Preliminary results from a phase 3 trial of a lung cancer treatment have been disappointing. AstraZeneca said it slowed the progression of the cancer, but the data on overall survival was “immature” and the results were not statistically significant. The trial will continue to assess overall survival in a more mature manner, the company said.

— CNBC’s Michelle Fox and Yun Li contributed reporting


Leave a Reply

Your email address will not be published. Required fields are marked *